Science Corp raises $400M Series D at reported $3.5bn, no lead named
TLDR
- Science Corporation raised a $400M Series D; a source told TechCrunch it values the company at $3.5bn.12
- Backers include Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech; no lead was named.1
- Money goes to PRIMA in Europe, preparing a US launch (HDE approval sought) and a biohybrid brain programme.1
Science Corporation, the medical technology start-up founded in 2021 by former Neuralink president Max Hodak, announced a $400M Series D on 17 November.2 Its post says the round brings total capital raised since 2021 to "more than $900 million".1 The post gives no valuation. TechCrunch reported that a person familiar with the deal put it at $3.5bn, and Bloomberg, relayed by Investing.com (which labels its piece as generated with the support of AI and reviewed by an editor), also reported $3.5bn.23 Science says the money will go towards wider PRIMA availability in Europe, preparing a US launch, expanded research and manufacturing, and "substantial further investments" in its biohybrid programme.1
S&P Capital IQ, via MarketScreener, which does not say where its data comes from, lists Khosla Ventures and Y Combinator as returning investors and the Ackman Oxman Institute, Tenet Healthcare, 885 Capital and PLC Neurotech Fund I, managed by Protocol VC, as new.4 It describes the shares as convertible preferred and the $3.5bn as post-money.4 Science's post does not name a lead, and neither TechCrunch, the Investing.com summary of Bloomberg nor MassDevice does.1235 The March Series C announcement had already called Khosla and Y Combinator pre-existing investors.6
Bloomberg describes the Ackman Oxman Institute as a brain research centre established this year by Bill Ackman and Neri Oxman.3 Fortune reported that the non-profit is being launched with roughly $400M in Pershing Square stock, according to Ackman's own post, and plans its own venture funding operation.7 Ackman wrote that the institute would help the blind see again "including by assisting existing companies in the space".7
PRIMA is a photovoltaic chip placed in the back of the eye, paired with camera-equipped glasses, for age-related macular degeneration.5 The company says a CE mark from DEKRA authorises commercial availability across 30 European countries, and that 84 per cent of the 38 patients in its NEJM-published trial reported being able to read letters, numbers and words (figures as presented by the company).8 Bloomberg reported two commercial implants in Germany with dozens more scheduled, and a spokesperson said Italy, France and the UK would be available soon; the price was not disclosed.3
In the US, Science says it is pursuing approval through the Humanitarian Device Exemption.1 Its July announcement says PRIMA holds Humanitarian Use Device designations, but that the device must still be reviewed and approved by the FDA through that exemption.9 Bloomberg reported that the company has submitted PRIMA to the FDA for approval, and that Hodak, the chief executive, expects US availability in the first half of next year; that is an expectation, not a regulatory decision.3
The valuation step is large. Science announced a $230M Series C on 5 March, taking total funding to about $490M, according to the company.6 Crunchbase News said the prior raise was a $104M convertible note led by Khosla in April 2025.10 TechCrunch reported, citing a source close to the startup, that the Series C was at a $1.5bn post-money valuation, which Science did not disclose.11 The reported $3.5bn is about 2.3 times that, by our arithmetic. Adding $400M to the $490M gives $890M, so the company's "more than $900 million" is not itemised in what we found.
Value Add VC argues that until Science publishes implant counts or revenue, the valuation is a bet on the US filing, not on sales.12
Not disclosed: the lead investor, each investor's cheque, revenue, the number of implants beyond Bloomberg's two, and a confirmed US launch date.
Why it matters: an implant the company says restores vision, with a CE mark but no US approval yet, is reported at $3.5bn on unnamed-source reports, with trial results as presented by the company and a US route that is still pending.289
Sources
- Science Series D (Science Corporation)
- Science Corporation's brain tech is worth $3.5 billion after new funding (TechCrunch)
- Science Corp valuation hits $3.5B on retina chip funding - Bloomberg (Bloomberg (via Investing.com))
- Science Corporation announced that it has received $400 million in funding from Khosla Ventures, LLC, Y Combinator Management, LLC, Ackman Oxman Institute, Tenet Healthcare Corporation, 885 Capital, Protocol VC LLC, and other investors (S&P Capital IQ (via MarketScreener))
- Science Corp. collects $400M to support retinal vision-restoring implant (MassDevice)
- Science Closes $230 Million Series C to Fund Commercialization of PRIMA BCI Retinal Implant and Expansion of Clinical Trials (Science Corporation)
- Billionaire Bill Ackman launches $400 million institute after daughter's brain hemorrhage (Fortune)
- Science Corp. Announces European Commercial Launch of PRIMA, the Only Treatment to Restore Functional Central Vision to Patients with Geographic Atrophy Caused by Age-Related Macular Degeneration, a Leading Cause of Blindness (Science Corporation)
- PRIMA Has Received Humanitarian Use Device Designations from the US Food and Drug Administration (Science Corporation)
- Science Corp., Another Braintech Startup Founded By Neuralink Alums, Raises $230M Series C (Crunchbase News)
- Science Corp. raises $230M as it races to bring its brain implant to market (TechCrunch)
- Science Corp raises $400M at reported $3.5B valuation (Value Add VC)